2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3512 Disease-biased IGH repertoire signatures provide auxiliary clues for diagnostically unclassifiable small B-cell lymphomas

Yuting Yan, MD, Tianyu Ma2, Weihao Chen3, Jun Wang4, Xinyi Zhang5, Ying Yu6, Tingyu of Wang7, Gang An, MD8, Lu-Gui Qiu, PhD9, Liang Wang Sr, MD, PhD10, Shuhua Yi, DO11
1 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Shandong Second Medical University, Weifang, China
3 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 Shengli Oilfield Central Hospital, Dongying, China
11 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: Small B-cell lymphomas (SBL) can remain unclassifiable after integrated morphologic, immunophenotypic, genetic, and clinical evaluation because of substantial phenotypic overlap. Each clonal B-cell population preserves an immunoglobulin heavy-chain (IGH) immunogenetic fingerprint comprising V(D)J segment usage, somatic hypermutation (SHM), and complementarity-determining region 3 (CDR3) architecture. We tested whether disease-biased IGH repertoire features could provide orthogonal evidence to refine the differential diagnosis rather than merely document clonality.

Methods: We retrospectively analyzed 1 representative diagnostic sample per patient from 2000–2025. The reference cohort comprised 3,440 patients with an integrated diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; n=1,932), Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL; n=450), marginal zone lymphoma (MZL; n=458), mantle cell lymphoma (MCL; n=253), follicular lymphoma (FL; n=217), hairy cell leukemia (HCL; n=94), or HCL variant (n=36). A nonoverlapping application cohort comprised 264 cases that remained unclassifiable after integrated evaluation. Clonal IGHV–IGHD–IGHJ rearrangements were sequenced bidirectionally by Sanger sequencing and annotated with IMGT/V-QUEST and NCBI IgBLAST. IGHV sequences with <98% germline identity were classified as mutated. For each segment, the target entity was compared with all other reference entities using Fisher's exact test, with Benjamini–Hochberg correction separately for IGHV, IGHD, and IGHJ.

Results: The mutated IGHV fraction varied markedly across reference entities, from 40.3% in MCL to 98.6% in FL (CLL/SLL, 66.9%; MZL, 69.0%; HCL, 80.9%; HCL variant, 80.6%; WM/LPL, 94.0%).  Ten disease-biased segments were retained: IGHV1-69 (CLL, OR=2.42, Q=0.0001); IGHV1-2*04 (MZL, OR=48.23) and IGHD3-10*01 (MZL, OR=1.74, Q=0.023); IGHV1-8 and IGHV3-21 (MCL, OR=9.49 and 6.80); IGHV3-11*01, IGHV3-48 and IGHV3-66 (FL, OR=6.28, 3.15 and 3.84); and IGHV3-73 and IGHV3-74 (LPL/WM, OR=5.43 and 2.37). Applying the library to the 264 unclassifiable cases identified >=1 disease-biased feature in 46 (17.4%): MZL-like 12 (4.5%), FL-like 10 (3.8%), LPL/WM-like 10 (3.8%), MCL-like 8 (3.0%), and 6 (2.3%) carrying features of more than one entity; no case matched the CLL-biased segment. The unclassifiable cohort was mutation-predominant (81.1% mutated; 9.1% unmutated), resembling LPL/WM (94.0% mutated), HCL (80.9%) and MZL (69.0%). Within each entity, HCDR3 length differed significantly between cases expressing the entity-associated IGHV gene and those using other IGHV genes: CLL (IGHV1-69, P<0.0001), MCL (IGHV3-21, P<0.0001), MZL (IGHV1-2*04, P<0.0001) and LPL/WM (IGHV4-34, P=0.0002), indicating that V-gene choice and junctional length are non-independent and jointly shape entity-associated clonotypes. Stereotypy was informative but not entity-exclusive: 208 reference cases mapped to 23 of 29 major subsets (192 CLL, 6 LPL/WM, 4 MZL, 4 FL, 2 MCL), and 380 cases formed 145 minor clusters, of which 69 (47.6%) spanned more than one diagnosis, most often CLL with LPL/WM (n=21) or MZL (n=18). Sharing was nonetheless well below chance (71.2% mixed clusters under permutation, P<0.0001; weighted purity 0.76 vs 0.65, P<0.0001), indicating genuine but incomplete diagnostic restriction of convergent BCR selection. No unclassifiable case mapped to any subset or cluster.
Conclusions:  Across 3,704 SBCL cases, IGH clonotypic architecture is diagnostically restricted but not entity-exclusive: stereotyped clusters segregate by diagnosis far more than chance yet are shared across entities in nearly half of instances, consistent with partially convergent antigen-driven selection. A conservatively curated disease-biased IGH library provided a supportive entity-directed clue in 17.4% of otherwise unclassifiable SBCL, most often MZL-like or LPL/WM-like, using assays already embedded in routine clonality workflows and requiring no additional platform. These features denote relative enrichment rather than diagnostic biomarkers and must be integrated with morphology, immunophenotype and genetics. Multicenter validation with formal accuracy metrics and outcome-anchored reference diagnoses is warranted.

Yuting Yan, MD: No relevant conflicts of interest to declare.